|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Spondyloarthritis encompasses a group of common inflammatory diseases thought to be driven by IL-17A-secreting type-17 lymphocytes.
|
29142230 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Spondyloarthritis (SpA), a chronic inflammatory, rheumatic disease, and hidradenitis suppurativa (HS), a chronic, debilitating, inflammatory skin disease, share several clinical and pathophysiological features, such as the association with inflammatory bowel disease and elevated cytokine levels IL-17 and TNF-α.
|
29751976 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-17 and IFN-γ producing NK and γδ-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis.
|
28390966 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A has been identified as a master cytokine in the inflammatory response and pathogenesis of PsA and spondyloarthritis in general.
|
29187009 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-17A blockade was performed in HLA-B27/human β<sub>2</sub> -microglobulin (hβ<sub>2</sub> m)-transgenic rats, which served as a model for SpA in both prophylactic and therapeutic settings.
|
30390386 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-17 Inhibition in Spondyloarthritis Associates with Subclinical Gut Microbiome Perturbations and a Distinctive IL-25-Driven Intestinal Inflammation.
|
31729183 |
2020 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cell surface HLA-B27 FHC binding to these immune receptors or acting through other mechanisms could impact on the pathogenesis of spondyloarthritis by promoting immune cell production of IL-17.
|
23910730 |
2014 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Clinical improvement in joint counts was associated with a histologic decrease in synovial sublining macrophages (P = 0.028) and neutrophils (P = 0.004), both of which are sensitive synovial biomarkers of inflammatory response in peripheral SpA, as well as with decreased synovial expression of IL-17A messenger RNA (mRNA) (P = 0.010) but not of tumor necrosis factor mRNA.
|
29869838 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cytokines from the IL-17 family have been shown to be involved in the pathogenesis of several diseases such as spondyloarthritis, psoriatic arthritis, or psoriasis.
|
31485194 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Despite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti-Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL-23/IL-17 pathway often provide prolonged, deep responses and in some cases even remission (3).
|
31736273 |
2020 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.
|
30266977 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, IL-17 and IL-23 inhibitors reduce the clinical manifestations of SpA.
|
28850053 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, mast cells expressed significantly more interleukin-17 (IL-17) in SpA than in RA synovitis, and mast cells constituted the major IL-17-expressing cell population in the SpA synovium.
|
21968742 |
2012 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, the contribution of IL-17-producing γδ T cells to SpA pathogenesis is certainly not an open-and-shut case.
|
29922283 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-7 is a cytokine whose ability to stimulate IL-17 production in both innate and adaptive immunity cells has made it a promising target not only for a better understanding of the disease as well as an important potential therapeutic target in patients with SpA.
|
31276000 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this Review, we discuss how IL-17A and IL-17F and their cellular sources might contribute to the immunopathology of SpA.
|
30006601 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, we will examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and discuss how these observations were translated into clinical practice.
|
28270233 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA.
|
28149838 |
2017 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Murine models of interleukin (IL)-23-driven spondyloarthritis (SpA) have demonstrated entheseal accumulation of γδT-cells which were responsible for the majority of local IL-17A production.
|
31530557 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis.
|
22269151 |
2012 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nevertheless, a number of knowledge gaps exist regarding the role of IL-17A in the pathophysiology of spondyloarthritis in man, including its cellular origin, its precise role in discrete disease processes such enthesitis, bone erosion, and bone formation, and the reasons for the discrepant responses to IL-17A inhibition observed in certain other spondyloarthritis manifestations.
|
31278139 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Other targeted cytokines associated with IL-17 axis in SpA will also be included.
|
29670461 |
2018 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
RGD |
Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats.
|
21905004 |
2012 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients.
|
30602780 |
2019 |
|
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Targeted Delivery of the HLA-B<sup>∗</sup>27-Binding Peptide into the Endoplasmic Reticulum Suppresses the IL-23/IL-17 Axis of Immune Cells in Spondylarthritis.
|
29463951 |
2017 |